ETNB Share Price | 89bio, Inc. Stock Analysis & Recommendation

Q: How big is 89bio, Inc.?

Market Cap: As of Jun 18, 89bio, Inc. has a market capitalization of 1,451.08 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, 89bio, Inc. reported net sales of 0.00 million and a net profit of -386.67 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 400.79 million and total assets of 478.69 million.

Q: What does 89bio, Inc. do?

Overview:89bio, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for liver and cardio-metabolic diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Profit: -71 Million (Quarterly Results - Mar 2025)Market cap: USD 1,451.08 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Industry P/E: NADividend Yield: 0.00%Debt Equity: -0.99Return on Equity: -63.86%Price to Book: 2.40Contact Details:Address: 535 Mission St Fl 14, San Francisco CA 94105-3253Tel: 1 415 5004614Website: https://www.89bio.com/

Q: Is 89bio, Inc. technically bullish or bearish?

As of 10 October 2025, the technical trend for 89bio, Inc. has changed from bullish to mildly bullish. The weekly MACD and KST indicators are bullish, while the moving averages on a daily basis also indicate bullishness. However, the weekly and monthly RSI readings are bearish, suggesting some weakness. The Bollinger Bands show a mildly bullish stance on the weekly and bullish on the monthly. The OBV is mildly bearish on the weekly timeframe. In terms of returns, the stock has significantly outperformed the S&P 500 over the past month (83.4% vs. 0.31%) and year-to-date (89.26% vs. 11.41%), but has underperformed over the longer three-year and five-year periods. Overall, the current stance is mildly bullish, with mixed signals from various indicators.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

Shareholding (Mar 2025)

FII

16.42%

Held by 97 FIIs

DII

56.62%

Held by 44 DIIs

Promoter

1.41%

How big is 89bio, Inc.?

22-Jun-2025

As of Jun 18, 89bio, Inc. has a market capitalization of $1.45 billion, with net sales of $0.00 million and a net profit of -$386.67 million over the last four quarters. The company reported shareholder's funds of $400.79 million and total assets of $478.69 million as of Dec 24.

View full answer

What does 89bio, Inc. do?

22-Jun-2025

89bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and cardio-metabolic diseases, with a market cap of approximately $1.45 billion and a recent net profit of -$71 million. The company operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap entity.

View full answer

Who are in the management team of 89bio, Inc.?

22-Jun-2025

As of March 2022, the management team of 89bio, Inc. includes Dr. Steven Altschuler (Independent Chairman), Mr. Rohan Palekar (CEO and Director), and five Independent Directors: Dr. Derek DiRocco, Dr. Gregory Grunberg, Dr. Michael Hayden, and Ms. Anat Naschitz.

View full answer

Is 89bio, Inc. technically bullish or bearish?

14-Oct-2025

As of October 10, 2025, 89bio, Inc. shows a mildly bullish trend with mixed signals from indicators, having outperformed the S&P 500 recently but underperformed over longer periods.

View full answer

Compare 89bio, Inc. with Similar Stocks

Mirum Pharmaceuticals, Inc.SAGE Therapeutics, Inc.Amylyx Pharmaceuticals, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 2,204 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

48.81%

Debt Equity

-1.00

Return on Equity

-86.29%

Price to Book

4.22

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-112 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

107.55%

6 Months

85.5%

1 Year

75.21%

2 Years

-26.9%

3 Years

335.19%

4 Years

-26.02%

5 Years

-44.34%

89bio, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-257.17%

EBIT to Interest (avg)

-55.07

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.99

Sales to Capital Employed (avg)

Tax Ratio

0.19%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.47

EV to EBIT

-2.22

EV to EBITDA

-2.22

EV to Capital Employed

265.43

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-11970.56%

ROE (Latest)

-63.86%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

No Trend

Bearish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 56 Schemes (25.56%)

Foreign Institutions

Held by 97 Foreign Institutions (16.42%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -132.29% vs -25.00% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-115.80",
          "val2": "-53.40",
          "chgp": "-116.85%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.10",
          "val2": "0.90",
          "chgp": "22.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-111.50",
          "val2": "-48.00",
          "chgp": "-132.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -158.16% vs -39.41% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-384.60",
          "val2": "-150.90",
          "chgp": "-154.87%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "3.80",
          "val2": "3.60",
          "chgp": "5.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.50",
          "val2": "-1.20",
          "chgp": "-25.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-367.10",
          "val2": "-142.20",
          "chgp": "-158.16%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-115.80

-53.40

-116.85%

Interest

1.10

0.90

22.22%

Exceptional Items

0.00

Consolidate Net Profit

-111.50

-48.00

-132.29%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -132.29% vs -25.00% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-384.60

-150.90

-154.87%

Interest

3.80

3.60

5.56%

Exceptional Items

-1.50

-1.20

-25.00%

Consolidate Net Profit

-367.10

-142.20

-158.16%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -158.16% vs -39.41% in Dec 2023

All Annual Results

Company CV

About 89bio, Inc.

89bio, Inc.

Pharmaceuticals & Biotechnology

89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, BIO89-100, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH). FGF21 is a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism.

Company Coordinates

Company Details

535 Mission St Fl 14 , San Francisco CA : 94105-3253

Tel: 1 415 5004614

https://www.89bio.com/

Registrar Details

89bio, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is 89bio, Inc.?

Watch in Real-Time

What does 89bio, Inc. do?

Who are in the management team of 89bio, Inc.?

Is 89bio, Inc. technically bullish or bearish?

Compare 89bio, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About 89bio, Inc.

Company Coordinates